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1. Introduction 
Salmonella enterica serovars continue to be among the most important foodborne pathogens 
worldwide due to the considerable human rates of illness reported and the wide range of 
hosts that are colonized by members of this genus, which serve as vectors and reservoirs for 
spreading these agents to animal and human populations. Furthermore, public concern for 
the appearance of resistant strains to many antibiotics, particularly among zoonotic 
pathogens such as common Salmonella isolates, is also challenging the poultry industry to 
find alternative means of control (Boyle, Bishop, Grassl, & Finlay, 2007). For example, in 
January 2006 Europe implemented a complete ban on growth promoting antibiotics in 
animal feed (Anadon, Martinez-Larranaga, & Aranzazu Martinez, 2006). Thus, while 
attempting to control human foodborne pathogens poultry producers are simultaneously 
challenged to improve production in the face of increasing feed costs while using fewer 
antibiotics due to increased restriction of antimicrobial usage. These regulations were 
implemented because of export market restrictions and consumer or customer preferences 
in local markets. For these reasons continued research on sustainable alternatives to 
antibiotic growth promoters for animal production such as probiotics or direct fed 
microbials (DFM) consisting of live or dead organisms and spores (Patterson & Burkholder, 
2003), non-traditional chemicals (Ko, Mendoncam, Ismail, & Ahn, 2009), bacteriophages 
(Andreatti Filho et al., 2007; Bielke, Higgins, Donoghue, Donoghue, & Hargis, 2007; J. P. 
Higgins et al., 2005; J. P. Higgins, Andreatti Filho et al., 2008), organic acids and other plant 
extracts and essential oils (Aengwanich & Suttajit, 2010; Allen-Hall, Arnason, Cano, & 
Lafrenie, 2010; Bagchi et al., 2000; Kubena, Byrd, Young, & Corrier, 2001; Over, 
Hettiarachchy, Johnson, & Davis, 2009; Van Immerseel et al., 2006), and vaccines (Kremer et 
al., 2011; O’Meara et al., 2010; Wolfenden et al., 2010; Van Immerseel et al., 2005; Dueger et 
al., 2001, 2003) are increasingly more important. These potential solutions have emerged in 
the last decade as tools that could be potentially useful in the near future for pathogen 
control and poultry performance improvement.  
Probiosis, although not a new concept, has only recently begun to receive an increasing level 
of scientific interest. In agriculture, probiotics and DFMs used in animal feed are becoming 
accepted as potential alternatives to antibiotics for use as growth promoters, and in select 
cases, for control of specific enteric pathogens (Anadón, Rosa Martínez-Larrañaga, & 
Aranzazu Martínez, 2006; Boyle et al., 2007; Cartman, La Ragione, & Woodward, 2008; Vila 
et al., 2009; L. D. Williams, Burdock, Jimenez, & Castillo, 2009). For these reasons the 
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development of new and more effective probiotic products that can be licensed for animal 
use continues to receive considerable interest (Hong, Duc le, & Cutting, 2005; Hong, Huang, 
Khaneja, Hiep, Urdaci, & Cutting, 2008a; Jadamus, Vahjen, & Simon, 2001; Osipova, 
Makhailova, Sorokulova, Vasil'eva, & Gaiderov, 2003; P. Williams, 2007b; Wolken, Tramper, 
& van der Werf, 2003). 
Currently, there is no universal class of probiotic bacterium. However, the most common 
types that have been indisputably effective involve LAB. These bacteria are found normally 
in the gastrointestinal tract (GIT) of vertebrates and invertebrates, and the use of some LAB 
cultures are able to restore the natural microflora within the gut (Shahani & Ayebo, 1980). 
Lactic acid bacteria include the genera Lactobacillus, Pediococcus, and others that have long 
been associated with health benefits and which have been used for fermentation of certain 
foods. While speciation of members of these genera is difficult and inconsistent, these 
organisms are considered uniformly safe and are not associated with disease in healthy 
animals or humans (Tellez et al., 2006). 
A second classification of probiotic cultures are those microorganisms that are not normally 
found in the GIT (such as allochthonous flora). For example, Saccharomyces boulardii, a strain 
of yeast found on some tropical fruits, has been shown to be effective in preventing the 
recurrence of Clostridium difficile infections (Czerucka, Piche, & Rampal, 2007) and some 
colibacillosis in humans (Czerucka& Rampal, 2002). Otherallochthonous probiotic microbes 
are the spore-forming bacteria, normally members of the genus Bacillus.  
2. Lactic acid bacteria-based probiotic for Salmonella control and 
performance in poultry 
The selection of individual enteric bacteria capable of inhibiting Salmonella growth in vitro and 
the ability of selected oxygen-tolerant bacteria to also protect neonatal poults and broilers from 
Salmonella infection following challenge has been a goal of multiple research laboratories 
(Menconi et al., 2011; Vicente et al., 2008; Bielke et al., 2003; Hollister et al., 1999; Corrier et al., 
1998; Hume et al., 1998). Tellez and co-workers (2006) evaluated a simple method to select for 
individual enteric bacteria capable of inhibiting Salmonella growth in vitro and the ability of 
selected oxygen tolerant bacteria, in combination, to protect neonatal poults from Salmonella 
infection following challenge. Concurrently, they also worked toward the isolation, selection, 
further evaluation and combination of LAB to control additional foodborne pathogens. 
Extensive laboratory and field research conducted with this defined LAB culture has 
demonstrated accelerated development of normal microflora in chickens and turkeys, 
providing increased resistance to Salmonella spp. infections (Farnell et al., 2006; J. P. Higgins et 
al., 2007; J. P. Higgins et al., 2008; J. P. Higgins et al., 2010; S. E. Higgins et al., 2008; Vicente et 
al., 2008). Published experimental and commercial studies have shown that these selected 
probiotic organisms are able to reduce idiopathic diarrhea in commercial turkey brooding 
houses (S. E. Higgins et al., 2005). Large scale commercial trials indicated that appropriate 
administration of this probiotic mixture to turkeys and chickens increased performance and 
reduced costs of production (Torres-Rodriguez et al., 2007a; Torres-Rodriguez et al., 2007b; 
Vicente et al., 2007a; Vicente et al., 2007b; Vicente et al., 2007c). 
These data have clearly demonstrated that selection of therapeutically efficacious probiotic 
cultures with marked performance benefits in poultry is possible, and that defined cultures 
can sometimes provide an attractive alternative to conventional antimicrobial therapy 
(seehttp://www.pacificvetgroup.com/ for more information).  
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3. Mechanism of action of probiotics against Salmonella 
Probiotics are defined as live microorganisms that, when administered in adequate 
amounts, confer a health benefit on the host. Amongst the many benefits associated with 
the consumption of probiotics, modulation of the immune system has received 
considerable attention (Borchers, Keen, & Gershwin, 2002; Borchers, Selmi, Meyers, Keen, 
& Gershwin, 2009).  
Previously, it was thought that administration of bacteria such as probiotics to neonates 
directly reduced infection by pathogens due to competition amongst the bacteria for 
attachment sites and nutrients and, that beneficial bacteria would out-compete pathogens 
within the GIT. This competition, coined as “competitive exclusion” was first described in 
1973 by Nurmi and Rantala (Nurmi& Rantala, 1973). Their data indicated that early 
administration of beneficial bacteria to chicks prevented infection by pathogens. Since 
Nurmi and Rantala proposed competitive exclusion could be used as a method to prevent 
Salmonella infection, numerous researchers have reported the ability of live bacterial cultures 
to also reduce colonization of opportunistic microorganisms in the gastrointestinal tract 
(Callaway et al., 2008; Wagner et al., 2003; Hollister et al., 1999; Corrier et al., 1998; Hume et 
al., 1998; Nisbet et al., 1998) and probiotic organisms (J. P. Higgins et al., 2010; S. E. Higgins 
et al., 2008; Vicente et al., 2008; J. P. Higgins et al., 2007; Bielke et al., 2003; Patterson & 
Burkholder, 2003). Yet, understanding of how probiotics mediate these health benefits, 
specifically reduction of Salmonella infection, is very limited.  
Balanced gastrointestinal microflora and immune-stimulation are major functional effects 
attributed to the consumption of probiotics (Amit-Romach, Uni, & Reifen, 2010; Boirivant & 
Strober, 2007; Boirivant, Amendola, & Butera, 2008; Flint, O'Toole, & Walker, 2010; Flore, 
Francois, & Felicite, 2010; Ibrahim et al., 2010; Klein, Sanders, Duong, & Young, 2010; Nayak, 
2010). Many probiotic effects are mediated through immune regulation, particularly through 
balance control of pro-inflammatory and anti-inflammatory cytokines (Di Giacinto, 
Marinaro, Sanchez, Strober, & Boirivant, 2005; Foligne et al., 2010; Hacini-Rachinel et al., 
2009; Jobin, 2010; Li, Xia, & Li, 2009). However, several animal and human studies have 
provided unequivocal evidence that specific strains of probiotics are able to stimulate 
multiple aspects of innate immunity (Amit-Romach et al., 2010; Boirivant & Strober, 2007; 
Boirivant et al., 2008; Farnell et al., 2006; Romanin et al., 2010; Weiss et al., 2010) as well as to 
increase humoral immunity (Fang, Elina, Heikki, & Seppo, 2000; Galdeano, de Leblanc Ade, 
Carmuega, Weill, & Perdigon, 2009; Leblanc, Fliss, & Matar, 2004; Nermes, Kantele, Atosuo, 
Salminen, & Isolauri, 2011). 
Using a Salmonella challenge model, an effective LAB probiotic, administered 2 hours after 
Salmonella challenge, had no effect during the first 12 hours on increasing cecal colonization by 
this pathogen, although marked and rapid decreases were observed between 12 and 24 hours 
post-challenge (J. P. Higgins et al., 2007; J. P. Higgins et al., 2010). Later, using the same model 
and microarray analysis of gut mRNA expression, gene expression differences in birds treated 
with a Lactobacillus-based probiotic were compared to saline treated birds. At 12h post-
probiotic treatment, 170 genes were significantly different (P<0.05), but by 24h post treatment, 
the number of differentially regulated genes were 201. Pathway analysis revealed that at both 
time points, genes associated with the NFκB complex were significantly regulated, as well as 
genes involved in apoptosis. Probiotic-induced differential regulation of the genes GAS2 and 
CYR61 may result in increased apoptosis in the ceca of chicks. Because Salmonella is an 
intracellular pathogen, it was suggested that increased apoptosis may be a mechanism by 
which B11 reduces Salmonella infection (S. E. Higgins et al., 2011).  
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4. Comparisons between genotypic 16S rRNA, MIDI, and biolog 
identifications of FloraMax
TM
 lactic acid bacteria 
A well-characterized LAB-based probiotic has been investigated in numerous studies (Tellez 
et al., 2006; Torres-Rodriguez et al., 2007a; Torres-Rodriguez et al., 2007b; Vicente et al., 
2007a; Vicente et al., 2007b; Vicente et al., 2007c) and has now been commercialized (Pacific 
Vet Group USA Inc., Fayetteville AR 72703). Struggles with speciation of the LAB isolates 
during development of this product illustrate the well recognized problem for speciation of 
LAB. The identification techniques of choice for many facultative anaerobes are biochemical 
analyses, but the standard identification system for lactic acid bacteria is cellular fatty acid 
profiling. Nevertheless, these phenotypic methods can yield variable results. Genotypic 
methods that rely on comparisons of 16S rRNA sequences from unknown bacteria are 
proving to be valuable for use in a wide range of genera and are not sensitive to variable 
culture conditions. Genotypic 16S rRNA identification of organisms from probiotic cultures 
may be more consistent than the current standard microbial techniques applied separately 
to different microbial groups. However, this approach comes with its own limitations and 
issues. As identification is based on specific sequence homology as compared with a known 
database of microflora previously identified through conventional methodologies, the 
speciation is dependent upon the closest match with what was previously identified, 
correctly or incorrectly, in the database. As databases constantly expand and change, the 
same sequence submission over time may match other names with greater homology. Thus, 
at this moment, it is nearly impossible to really know the speciation of LAB except under 
specific examples with very highly characterized isolates. In fact, 16S rRNA sequencing of 
isolates from internationally-known name brands of commercially-produced yogurt with 
live cultures has consistently resulted in database matches with LAB species that are labeled 
as other species on the yogurt labels (unpublished). Thus, while 16s RNA sequencing can 
positively identify one LAB isolate as unique among several, true accuracy of homology 
comparisons is a somewhat subjective exercise.  
Even though there are many new experimental molecular identification techniques, such as 
microarray hybridization, sequence analysis of 16S rRNA is the predominant molecular 
technology presently available for microbial identification of these commensal microorganisms 
(Wagner et al., 2003), even with the known problem of database accuracy and consistency over 
time. The detailed information needed to identify each species represented in a commercial 
probiotic product can only be fully obtained from the 16S rRNA at the level of the nucleotide 
sequence. As an example, an identification scheme was designed using the MIDI System ID 
from two different private laboratories (Micro Test Lab Inc., Agawam, MA 01001, USA; and 
Microbial ID Inc., Newark, DE 19713, USA) the Biolog ID System (Biolog, Inc., Hayward, CA 
94545, USA) and compared those results with the 16S rRNA Sequence Analyses (Microbial ID 
Inc., Newark, DE 19713, USA) for identification of the individual component bacteria present 
in the commercial probiotic FloraMaxTM (Table 1). The results of that study showed that the 
complex populations of bacteria present in FloraMaxTM are not easy to accurately identify, 
especially with phenotypic techniques. Conventional technologies can detect human 
pathogens, because they are well-established in comparative databases, but emerging and 
opportunistic pathogens are not. Despite the fact that uncertainty exists between different 
methods of identification of non-pathogenic probiotic bacteria, identification of known 
pathogens is much more consistent. Therefore, the use of fully defined cultures for competitive 
exclusion or probiotic use are still inherently safer than undefined cultures or those where 
organisms are identified after the culture has been produced. 
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LAB 
ID 
16S RNA 
Sequencing 
(FIRST 500 bp) 
Microbial ID Inc. 
Midi system ID 
Micro Test Lab 
Inc. 
Midi system ID 
Microbial ID Inc. 
Biolog ID 
Dept. of Poultry 
Sc. 
U. of Arkansas 
18 
Pediococcus 
parvulus 
Enterococcus 
cecorum 
Lactobacillus 
gasseri 
Unable to identify 
24 Weissella confusa Lactobacillus casei Lactobacillus casei 
Clostridium 
clostridiiforme 
27 Weissella confusa Lactobacillus casei Lactobacillus casei Weissella confusa 
29 
Pediococcus 
parvulus 
Lactobacillus 
delbreuckii-
bulgaricus 
Lactobacillus 
delbreuckii-
bulgaricus 
Lactobacillus 
hamsteri 
36 
Lactobacillus 
salivaruis 
Lactobacillus 
cellobiosus 
Lactobacillus casei Weissella confusa 
37B Weissella confusa 
Pediococcus 
acidilactici 
Pediococcus 
ruminis 
Unable to identify 
40 Weissella confusa Lactobacillus casei 
Lactobacillus 
cellobiosus 
Weissella 
paramesenteroides 
44 
Weissella 
paramesenteroides 
Lactobacillus 
fermentum 
Lactobacillus 
fermentum 
Unable to identify 
46 
Lactobacillus 
salivaruis 
Lactobacillus 
helveticus 
Lactobacillus 
sanfranciscensis 
Lactobacillus 
salivaruis 
48 
Lactobacillus 
salivarius 
Lactobacillus 
helveticus 
Lactobacillus 
gasseri 
Lactobacillus 
salivarius 
52 
Pediococcus 
parvulus 
Unable to identify 
Lactobacillus 
cellobiosus 
Unable to identify 
Table 1. Comparisons between MicroSeq , MIDI, and Biolog identifications of FloraMaxTM 
lactic acid bacteria1 
5. Bacillus spore-based probiotic for Salmonella control and performance 
enhancement in poultry 
In spite of the success showed by the development of the LAB probiotic for use in 
commercial poultry as described above, there is still an urgent need for commercial 
probiotics that are shelf-stable, cost-effective and feed-stable (tolerance to heat pelletization 
process) to increase compliance and widespread utilization. Among the large number of 
probiotic products in use today some are bacterial spore formers, mostly of the genus 
                                                                 
1Adapted from Tellez et al., 2006 
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Bacillus. Used primarily in their spore form, some (though not all) have been shown to 
prevent selected gastrointestinal disorders and the diversity of species used and their 
applications are astonishing. While not all Bacillus spores are highly heat tolerant, some 
specific isolates are the toughest life form known on earth (Vreeland, Rosenzweig, & 
Powers, 2000) and can be used under extreme heat conditions. Several studies have shown 
that either live vegetative cells or endospores of some isolates can prevent colon 
carcinogenesis (Parket al., 2007) or discharge antimicrobial substances against Gram-
positive bacteria, such as Staphylococcus aureus, Enterococcus faecium, and Clostridium difficile 
(O'Mahony et al., 2001). These results provided evidence of colonization and antimicrobial 
activity of probiotic bacteria, thus, products containing Bacillus spores are used 
commercially as probiotics, and they offer potential advantages over the more common LAB 
products since they can be used as direct feed microbials (Anadón et al., 2006; Barbosa et al., 
2005; Duc le et al., 2004; Hong et al., 2005; Hong et al., 2008a; Hong et al., 2008b; McNulty et 
al., 2007; Osipova et al., 2003; P. Williams, 2007a; Wolken et al., 2003). There is scientific 
evidence suggesting that some but not all isolates of ingested B. subtilis spores can, in fact, 
germinate in the small intestine (Casula & Cutting, 2002; Casula & Cutting, 2002; Duc le & 
Cutting, 2003; Hoa et al., 2001). Together, these studies not only show that spores are not 
transient passengers in the gut, but they have an intimate interaction with the host cells or 
microflora that can enhance their potential probiotic effect. Several commercial spore-
forming Bacillus cultures have been shown to reduce food borne pathogens (Aureli et al., 
2010). However, cost issues associated with achieving necessary concentrations of spores in 
feed have greatly limited commercial acceptance in the animal industry (Hong et al., 2005). 
While the majority of clear-cut research with regard to beneficial probiotic cultures has 
focused on LAB, as discussed above, a major question in several laboratories is whether or 
not selected spore-former bacteria (genus Bacillus or related) can be as effective as the best 
known LAB cultures. Recently, one Bacillus subtilis spore isolate was as effective as a well-
established LAB-based probiotic for Salmonella reduction in poultry (Wolfenden R.E. et al., 
2010; Shivaramaiah et al., 2011), and was equal to bacitracin for prevention of experimental 
necrotic enteritis, and was able to markedly reduce necrotic enteritis issues in large scale 
feed trials (unpublished from the author’s laboratory).  
Other isolates or combinations of isolates with increased potency and efficacy may be 
identified with continued research. Some of these environmental Bacillus isolates have been 
evaluated in vitro for antimicrobial activity against selected bacterial pathogens, heat 
stability, and the ability to grow to high numbers. Unpublished experimental evaluations 
have confirmed improved body weight gain as well as Salmonella sp. or Clostridium 
perfringens reduction in commercial turkey and broiler operations when compared with 
medicated (nitarsone) or control nonmedicated diets respectively. Indeed, preliminary data 
suggests that these isolates could be an effective alternative to antibiotic growth promoters 
for commercial poultry.  
Importantly, improved efficiency of amplification and sporulation is absolutely essential to 
gain widespread industry acceptance of a feed-based probiotic for ante mortem foodborne 
pathogen intervention, as well as cost effectiveness. Recently, both vegetative growth and 
sporulation rates have been optimized, which may lead to new efficiencies for commercial 
amplification and manufacture of a cost-effective product at very high spore counts 
(Wolfenden R.E. et al., 2010). In order to select even more effective isolates, current research 
is focused on the mechanistic action of new Bacillus candidates. Preliminary studies indicate 
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a potential mechanistic action of these new Bacillus candidates at least partially involve 
rapid activation of innate host immune mechanisms (system or responses) in chickens and 
turkeys (unpublished data). This data provides an exciting possibility for identification of 
vastly superior and more potent probiotics in the near future. 
6. Prospects of bacteriophage therapy to control gastrointestinal disease 
6.1 Overview  
During the last approximately 60 years, there have been sporadic published reports of 
efficacy in treating Enterobacteriaceae infections systemically and within the gastrointestinal 
tract. While a number of reports have rather consistently indicated that systemic or tissue-
associated infections were treatable by parenteral administration of appropriate 
bacteriophage cocktails, reports of successful treatment of enteric Enterobacteriaceae are 
much more sporadic, and are interspersed with a number of reports of failed attempts for 
enteric treatment. The following sections will discuss selected successes and failures and 
describe the possible differences in these studies and the potential for development of more 
effective strategies.  
6.2 Successes 
The bacteriocidal effects of bacteriophages have long been studied for their usefulness in 
treating gastrointestinal infections. Early studies originating from the former Soviet Union, 
Eastern Europe, and Eastern Asia suggested bacteriophages could prevent and treat Vibrio 
cholera infections (Dubos et al, 1943; Dutta, 1963; Sayamov, 1963; and Marčuk et al, 1971). In 
the 1980s Slopek and co-workers (1983a-b, 1984, 1985a-c, 1987) published numerous papers 
showing the promising results of treating septic patients with bacteriophages. While the 
validity of these studies has been questioned, in part due to relaxed scientific rigor in these 
regions during the time when these studies were completed (Merril et al, 2003; Alisky et al, 
1998) and are not often cited by bacteriophage researchers in recent years, they have served 
as an inspiration for continued research into the possibility that bacteriophages can cure 
gastrointestinal diseases in humans and animals. 
Smith and Huggins (1982) compared the efficacy of phages with that of antibiotics in treating 
both generalized and cerebral infections in mice. They isolated anti-K1 bacteriophages that 
were able to lyse K1-positive E. coli. These bacteriophages were able to cure infection caused 
by K1-positive, even when used at a low titer. The bacteriophages were more effective than 
several antibiotics for curing mice. Smith and Huggins (1983) also successfully used 
bacteriophage therapy to treat calves, pigs, and lambs that had been infected with E. coli. 
Perhaps key to their success, they selected a bacteriophage that would lyse E. coli and also 
selected a second bacteriophage that would lyse the target E. coli that had become resistant to 
the first bacteriophage. In 1987, Smith and Huggins used bacteriophages to treat calves with E. 
coli-caused diarrhea. They selected their bacteriophages by administering E. coli to a calf 
followed by a bacteriophage cocktail. Bacteriophages able to survive the gastrointestinal tract 
were collected in the feces 24 hours post-administration. These bacteriophages were used to 
treat subsequent calves. Calves given bacteriophages within 24 hours of the onset of diarrhea 
recovered within 20 hours. Also, sick calves placed on litter that had been sprayed with 
bacteriophages recovered from diarrhea. Smith and Huggins noted that during the period of 
disease, bacteriophages continued to persist in the feces, but after recovery, bacteriophage 
numbers dropped dramatically. 
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Biswas et al. (2002) successfully cured Enterococcus faecium-infected mice with bacteriophage 
therapy. Mice were treated with bacteriophages just 45 minutes after infection with bacteria. 
Treatment at a multiplicity of infection (MOI) level of 0.3 to 3.0 was able to cure all of the 
infected mice. However, lower MOIs of 0.03 to 0.003 resulted in just 60% and 40% survival 
of mice, respectively. They also noted that bacteriophage treatment could be delayed for up 
to five hours after infection. However, if treatment was delayed for 18 or 24 hours, only 50% 
recovery was seen. 
Berchieri et al. (1991) treated broiler chickens infected with Salmonella typhimurium (ST) 
with bacteriophages and found that the levels of ST could be reduced by several logs, and 
mortality associated with ST was reduced significantly. However, ST was not eliminated 
and it returned to its original levels within six hours of treatment. Also, the 
bacteriophages did not persist in the gastrointestinal tract for as long as the Salmonella was 
present. In fact, bacteriophages persisted only as long as they were added to the feed. In 
order to be effective, bacteriophages had to be administered in large numbers, and soon 
after infection with ST. 
In 1998 Barrow et al. prevented morbidity and mortality in chickens using bacteriophages 
lytic for E. coli. When chickens were challenged intramuscularly with E. coli and 
simultaneously treated with 106 – 108 pfu of bacteriophages the mortality was reduced by 
100%. This study also demonstrated that bacteriophages can cross the blood brain barrier, 
and furthermore that they can amplify in both the brain and the blood. Similarly, a number 
of other researchers have shown that bacteriophages can be useful for treating non-enteric E. 
coli infections. Extensive research about the effects of bacteriophages on colibacillosis in 
broiler chickens has shown that bacteriophages can treat respiratory infections (Huff et al, 
2002a-b; Huff et al, 2003a-b). Treatment was most successful when bacteriophages were 
directly applied to the infected area or injected into the bloodstream. This observation is 
consistent with previous research discussed above. 
However, such successes do not necessarily translate into effective enteric treatments. Host-
associated pressure against pathogen infections may predispose systemic bacteriophage 
therapy toward success. In these cases, where bacteriophage(s) are used to treat systemic or 
tissue-associated infections, an acute efficacy of merely reducing the infection load by 90% 
or more, could greatly reduce mortality and reduce the duration and magnitude of disease. 
In the intestinal lumen, host pressures against the infection may not be as severe and many 
Enterobacteriaceae are capable of free living status within the gut without eliciting robust 
acquired immune responses from the infected animal. In these cases, a temporary reduction 
in enteric colonization may not be as likely to be curative, as discussed below.  
6.3 Failures 
As the history of published successful bacteriophage treatments of enteric disease is 
reviewed, it is readily evident that such reports, while often dramatic in effect, are relatively 
sporadic during the last approximately 60 years. Given that experimental failures frequently 
are not published, as the cause of failure can often not be ascertained, the authors suspect 
that history is replete with unpublished examples of failures to treat enteric 
Enterobacteriaceae infections.  
Our laboratory, and others, have demonstrated that resistance to bacteriophages selected 
against Salmonella isolates quickly occurs, often in a single passage (Bastias et al, 2010). 
When bacteriophage cocktails of 71 different bacteriophages selected for treatment of 
experimental Salmonella enteritidis infections in chickens, a brief reduction in enteric 
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colonization was noted during the first 24 hours, but rebound levels were similar to controls 
within 48 hours, even with repeated or continuous dosage of the bacteriophage cocktail 
(Higgins et al, 2007). Because of the demonstrated temporary reduction in enteric 
colonization in these studies, effective bacteriophages were demonstrably able to pass to the 
lower gastrointestinal tract. As continued treatments failed to maintain this reduction, 
development of resistance by the enteric Salmonella enteritidis is the most likely explanation.  
In order to potentially deliver higher levels of bacteriophage, several attempts to protect the 
bacteriophage cocktail through the upper gastrointestinal tract were made in our laboratory. 
Pre-treatment of infected poultry with antacid preparations designed to reduce the acidity 
of the proventriculus (true stomach) were successful in increasing the number of 
administered bacteriophage that successfully passed into the intestinal tract, but this 
treatment did not improve the outcome of bacteriophage treatment of Salmonella enteritidis 
infection (Higgins et al, 2007).  
An alternative approach is to select for alternative non-pathogenic bacteriophage hosts 
which could potentially “carry” bacteriophage through the gastrointestinal tract and, with 
continuous dietary administration of the non-infected alternative host bacterium, provide a 
means of amplification within the gut of the host (Bielke et al., 2007a). Bielke and co-workers 
demonstrated that non-pathogenic alternative hosts can be selected for some bacteriophages 
that were originally isolated using a Salmonella enteritidis target (2007b). This approach, 
which has potential utility for amplification of large numbers of phage without the necessity 
to thoroughly separate bacteriophage from a pathogenic target host, was also used to create 
a potential “Trojan Horse” model for protecting the bacteriophages through the upper 
gastrointestinal tract, thus potentially providing a vehicle for enteric amplification of those 
surviving bacteriophages. In these studies, neither the Trojan Horse approach, nor the 
continuous feeding of the alternative host bacteria as a source of enteric amplification, were 
effective in producing even more than a transient reduction in enteric Salmonella infections.  
Through these failures, many investigators have concluded that the escape of even a 
minority of target bacteria within the enteric ecosystem allows for almost immediate 
selection of resistant target bacteria and rebound to pre-treatment levels of infection may 
even exceed the levels of non-treated controls in some cases. 
6.4 Potential strategies to overcome failures 
Bacteriophage resistance is an important component of therapy to overcome before 
bacteriophages can really be a viable antimicrobial for infection. The generation time for 
bacteria is typically short enough that mutants with bacteriophage resistance can emerge 
within hours (Higgins et al, 2007; Lowbury and Hood, 1953). One possibly strategy to 
overcome this problem is administration of multiple bacteriophage isolates for treatment, 
but resistance is difficult, if not impossible, to predict and combining the correct cocktail of 
bacteriophages to overcome resistance would be a blind guess in most cases.  
The most success is likely to come from treating points in the system that are continually 
bombarded with bacteria that have not been previously subjected to the bacteriophages 
being used for treatment. Also important for this system is keeping exposure of the bacteria 
to bacteriophages to a minimal amount of time. If the bacteriophages interact with the 
bacteria for long periods of time, the bacteria will become resistant. Food and meat 
processing facilities are an excellent example. As live animals enter a processing facility, the 
bacteria have not likely been exposed to the bacteriophages used to treat the infection. This 
greatly increases the chances of success.  
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Higgins and co-workers (2005) successfully treated turkey carcasses at a processing facility 
with bacteriophages specific to the Salmonella to which they were infected. This process was 
effective when either an autogenous bacteriophage treatment targeted to the specific 
Salmonella strain infecting the turkeys was used, or a cocktail of nine wide host-range 
Salmonella-targeting bacteriophage were used. Similarly, a bacteriophage treatment for cattle 
carcass contamination has been effective at reducing the E. coli 0157:H7 load at processing 
has been developed and commercially licensed in the United States. These successes avoid 
development of bacteriophage resistance by applying treatment at a single point during 
production, in an environment where proliferation of the target organism is extremely 
limited. In this way, since the target organism is never intentionally exposed twice to the 
same treatment, resistance is unlikely to ever increase beyond the naturally-occurring 
resistance to the bacteriophage (or cocktail) used.  
One of the most well documented successes of published treatment of enteric 
Enterobacteriaceae infections with bacteriophages was the study of Smith and Huggins 
(1983) as described above. It is notable that in this successful study, the bacteriophage 
cocktail used was a combination of two bacteriophages, but the second was isolated using 
the target organism which was resistant to the first bacteriophage. This approach of 
selecting for bacteriophage isolates using target bacteria that are resistant to sequential 
bacteriophage treatments was not used in the work of Higgins et al (2007), or in several 
other published studies. Higgins and co-workers (2007) used a collection bacteriophages, 
independently isolated from different sources and with several different plaque 
morphologies, suggesting that a number of different bacteriophages were employed – and 
failed to persistently reduce enteric colonization.  
It is possible that one of the most notable exceptions to the many failures to treat enteric 
Enterobacteraceae infections during recent years, that of Smith and Huggins (1983), 
provides a singular clue as to the potential for enhancing the likelihood of enteric 
Enterobacteriaceae efficacy. It is possible that selection of multiple bacteriophages for the 
same target cell phenotype results in selection of bacteriophages that are effective through 
identical mechanisms of adhesion, penetration, replication, and release. When new 
bacteriophages are isolated for efficacy against sequentially resistant isolates of the target 
bacteria, and these are combined for administration as a cocktail, the ability of the target cell 
to shift phenotype may be severely limited, resulting in a much larger proportion of target 
cell reduction, thereby increasing the probability of elimination or cure.  
Clearly, widespread bacteriophage treatments with Enterobacteriaceae have not been 
adopted for any animal species during the last 60 years and successful research in this area 
has been modest and sporadic. Nevertheless, the occasional reports by reputable scientists 
in solid journals must indicate that there is potential for improved therapeutic efficacy of 
bacteriophages for this purpose. With the diminution of new antimicrobial pharmaceuticals 
and the widespread resistance among many pathogenic enteric Enterobacteriaceaes, a 
breakthrough in this area is sorely needed.  
7. Vaccination for control of Salmonella in poultry 
Killed whole-cell bacterins and live attenuated vaccines are the most common types of 
vaccines currently used in the poultry industry. Vaccination programs depend on the 
recognition of specific antigens, called epitopes, by the immune system of the host to 
prevent or reduce the spread of pathogenic viruses and bacteria. Because there are a large 
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number of Salmonella serovars, each with individual epitopes that do not elicit cross-
protection against other serovars, there has been little traditional emphasis on development 
of generic Salmonella vaccines. Primarily, killed vaccines, which generally must be 
administered parenterally (through injection), have been applied to protect against systemic 
infections, and although they have been shown to reduce colonization and shedding, the 
protection provided by these vaccines has limited ability to stop intestinal colonization. 
They predominantly stimulate both humoral (circulating IgM and IgG) and cell-mediated 
responses, but are quite ineffective at generating mucosal immunity as secretory IgA 
antibody stimulation is very low through this type of vaccination. This is important because, 
whereas both systemic (humoral and cell-mediated) and mucosal immunity can reduce the 
chances of disease and mortality, only the mucosal portion of this adaptive immune 
response is capable of protecting animals from infection. The key to inducing both an 
adaptive systemic and mucosal response has traditionally been through the use of the 
mucosa as a “portal of entry” for live but weakened (attenuated) vaccines. However, the use 
of such vaccines for protection against Salmonella infection have been tremendously limited 
due to the very large number of different antigens presented by the more than 200 serotypes 
that can infect domestic animals and man, with more than 38 of these commonly infecting 
poultry within the United States, as discussed below (Hargis et al., 2010).  
One approach to solving the problem of serotype variation among the common paratyphoid 
strains of Salmonella, which are often not a disease-causing problem for poultry but rather 
create a source of foodborne illness for consumers, is the identification of “universal 
epitopes” that are shared among all Salmonella isolates. This concept has been established for 
a number of pathogens and is based on the identification of a minor surface structure 
(antigen or epitope) which does not cause robust immune reaction during infection, but 
which can be targeted for protection if the antigen is presented in a way that tricks the 
animal into responding robustly. Some of these are relatively minor antigens which are 
highly conserved among related organisms – usually because they involve biological 
function. Since small peptide sequences that are biologically functional cannot vary in 
sequence, organisms that carry a mutation for such sequences are often either lethal or 
sufficiently detrimental to cause these to not be successful over time (Neirynck et al., 1999).  
A well-described example of this phenomenon is a small 23 amino acid peptide on the 
surface of Type A Influenza viruses named M2e. This peptide is part of an ion transport 
channel which is necessary for viral activation. Mutations in this sequence undoubtedly 
occur frequently, but since the 1918 Spanish Influenza outbreak, all Type A Influenza 
isolates share a highly conserved core sequence for this peptide (Layton et al., 2009). 
Although natural influenza infection does not result in a robust immune response to this 
peptide sequence, tricking the animal into producing a robust response has resulted in 
protective immunity in several animal species (Neirynck et al., 1999; Mozdzanowska et al., 
2003; Fiers et al., 2004; Zou et al., 2004). In recent years, the rapid increase in molecular 
biological techniques has led to the development of more sophisticated vaccines, of which 
live recombinant bacterial vectored vaccines are one of the most promising (Ashby et al., 
2005; Zhang et al., 2006; Duc et al., 2007; Kajikawa et al., 2007; Uyen et al., 2007; Yang et al., 
2007; Huang et al., 2008; Liu et al., 2008; Ceragioli et al., 2009; Deguchi et al., 2009). 
This type of vaccine uses a genetically modified bacterium to express a heterologous 
antigen. Oral live attenuated Salmonella vaccine vectors expressing recombinant foreign 
antigens have previously been shown to stimulate systemic, mucosal, humoral, and cell-
mediated immune responses against Salmonella (Mollenkopf et al., 2001; Koton and 
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Hohmann, 2004; Ashby et al., 2005). Salmonella vectors have the potential advantage of being 
extremely inexpensive to manufacture and, because they do not have to be injected and can 
be administered by spray or drinking water, they are much more acceptable for widespread 
administration to commercial poultry. 
Currently, some laboratories are exploiting this concept by identifying candidate 
antigens/epitopes that are evolutionarily conserved between the many different serotypes of 
Salmonella and which do not elicit a robust response when animals are infected with wild type 
Salmonella (or vaccinated with conventional vaccines), but which may protect against infection 
when delivered in an appropriate way using a recombinant vaccine platform (Wolfenden, RE 
et al., 2010; Kremer et al., 2011). Recently, bacterial carriers of antigens (vectors), including 
Salmonella Enteritidis and Bacillus subtilis, have been manipulated to express protein antigens 
to protect against bacterial, viral, and protozoal pathogens (Layton et al., 2009; O’Meara et al., 
2010; Kremer et al., 2011; Layton et al., 2011). These vaccines have an advantage over many 
other types of vaccines in that they are able to be delivered directly to a mucosal surface via 
nasal, ocular, or oral administration. Because most pathogens invade the host through a 
mucosal surface, an enhanced mucosal immune response is the only portion of acquired 
immunity that can markedly reduce the probability of an animal or flock to become infected, 
as discussed above. While prevention of morbidity and mortality alone are useful traits of 
conventional vaccines for most poultry disease-causing agents, in the case of the common 
Salmonella serotypes which cause foodborne illness, these isolates generally cause little or no 
disease in the animals. Thus, recombinant vaccines that are able to provide wide-range 
protection against common Salmonella serotypes of poultry, by mucosal presentation, may be a 
critical component for controlling this problem in the next few years.  
Along with presentation of conserved antigens through mucosally-administered 
recombinant vaccines, there is a need to trick the immune system of the animal to respond 
robustly to these recombinant bacteria that are not capable of infecting or causing disease. 
Co-expression of molecules that may enhance the immune response or may be recognized 
by receptors located on the mucosal surface of the gastrointestinal tract is a promising area 
of work. Several such molecules may enhance the response to these recombinant vaccines 
(Layton et al., 2009; O’Meara et al., 2010; Wolfenden et al., 2010).  
Presently, there are no broad-spectrum recombinant vaccines approved for use in 
agricultural animals to protect against the wide range of serotypes which plague poultry 
producers worldwide. Specific serotype vaccines, such as S. Enteritidis or S. Gallinarum, 
have gained considerable acceptance in countries with endemic problems with these more 
devastating serovars, particularly in breeders and table egg production chickens (see 
Shivaprasad, 1997, for a review). These vaccines generally do not provide robust protection 
against infection with even the identical serotype, and even less protection against 
heterologous serotypes (Hargis et al., 2010). However, there is a general consensus that 
some protection is provided and for valuable birds, these vaccines may offer a much-needed 
modicum of protection, though often through reduced persistence and shedding of the 
organism, thus limiting spread. For example, studies have shown that oil emulsion 
Salmonella Enteritidis bacterins administered to breeders caused a three log10 cfu/g cecal 
content reduction in recovery from progeny chicks (Inoue et al., 2008), and a two log10 cfu/g 
cecal content reduction in breeders after molting (Nakamura et al., 2004). Thus, these 
vaccines have value at the present time, especially for breeders and at-risk laying hens.  
Live-type vaccines with gene deletions assuring avirulence while allowing immunogenicity 
have been reported (Curtiss and Kelly, 1987; Dueger et al., 2003), and other specific deletion 
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mutants have been proposed (Zhang-Barber et al., 1999; Sydenham et al., 2000). Day-of-
hatch chicks vaccinated with this type of attenuated Salmonella vaccine have been shown to 
have serological protection to homologous and heterologous Salmonella serotypes, possibly 
through a mechanism similar to competitive exclusion (Hassan and Curtiss, 1994; Hassan 
and Curtiss, 1997; Dueger et al., 2003; Holt et al., 2003; Bohez et al., 2008). Furthermore, 
maternal antibodies can be demonstrated in eggs and chicks from breeders vaccinated with 
this vaccine. These antibodies were reported to reduce Salmonellae colonization and to 
provide protection to laying hens up to 11 months post-inoculation (Hassan and Curtiss, 
1997). However, susceptibility to antimicrobial agents commonly used in poultry 
production can reduce or eliminate the efficacy of live vaccines, and these vaccines are 
subject to the serotype limitations as discussed above.  
Autogenous vaccines provide for yet another mechanism for vaccinating poultry. In many 
(but not all) countries, there are regulatory provisions under certain circumstances for 
production of specific killed vaccines using the specific isolate plaguing a given poultry 
flock or complex. These “autogenous” Salmonella isolates are typically grown, killed and 
mixed with an adjuvant (a chemical that potentiates the immune response) for parenteral 
administration. Some veterinarians associated with valuable breeder flocks believe that 
these vaccines are highly preferred for vaccination against endemic and common serotypes 
for which no commercial vaccine exists.  
Taken together, there are tremendous future opportunities for manipulating the acquired 
immune response, particularly the mucosal secretory IgA response, for reduceing Salmonella 
infections in poultry. However, current vaccine availability is limited and progress is greatly 
needed on two fronts: 1) improving mucosal immune responses for Salmonella vaccines; and 
2) targeting shared protective epitopes for broad-spectrum serotype coverage for the 
paratyphoid Salmonellae that currently plague poultry producers world-wide. Currently-
available commercial vaccines are enjoying significant popularity due to the intense 
regulatory pressures facing meat and egg producing poultry, although applications are 
generally limited to breeder or layer flocks except under intense regulatory pressure.  
8. Conclusions 
The interest in digestive physiology and the role of microorganisms has generated data 
whereby human and animal well-being can be enhanced and the risk of disease reduced. 
New molecular techniques that allow an accurate assessment of the flora composition, 
resulting in improved strategies for elucidating mechanisms. Given the recent international 
legislation and domestic consumer pressures to withdraw growth-promoting antibiotics and 
limit antibiotics available for treatment of bacterial infections, probiotics can offer alternative 
options. New advances in the application of probiotics, are directed to produce significant 
changes in gut physiology and provide even higher levels of health as well as increase 
performance parameters in poultry.  
Metchnikoff founded the research field of probiotics, aimed at modulating the intestinal 
microflora (Dobrogosz, Peacock, & Hassan, 2010; Schmalstieg & Goldman, 2010; Weissmann, 
2010). However, other parts of the body containing endogenous microflora or problems 
relating to the immune system may also be candidates for probiotic therapy. Research has 
shown that probiotics have potential for human health issues such as: vaginal candidiasis 
(Ehrstrom et al., 2010; Ya, Reifer, & Miller, 2010); dental caries (Chen & Wang, 2010; Stamatova 
& Meurman, 2009); allergies (Gourbeyre, Denery, & Bodinier, 2011; Schiavi, Barletta, Butteroni, 
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Corinti, Boirivant, & Di Felice, 2010b); autoimmune diseases (Lavasani et al., 2010; Tlaskalova-
Hogenova et al., 2011); urogenital infections (Pascual, Ruiz, Giordano, & Barberis, 2010; Ruiz et 
al., 2009); atopic diseases (Hoang, Shaw, Pham, & Levine, 2010; Nermes et al., 2011); 
rheumatoid arthritis (Lee et al., 2010; Mandel, Eichas, & Holmes, 2010); and respiratory 
infections (Harikrishnan, Balasundaram, & Heo, 2010; Silvestri et al., 2010). Current research is 
still heavily biased toward gastrointestinal applications for probiotics, such as: chronic 
constipation (Bu, Chang, Ni, Chen, & Cheng, 2007; Coccorullo et al., 2010); chronic diarrhea 
(Preidis et al., 2011; Swidsinski, Loening-Baucke, Verstraelen, Osowska, & Doerffel, 2008); 
inflammatory bowel disease (Ng, Chan, & Sung, 2011; Vanderpool, Yan, & Polk, 2008); 
irritable bowel syndrome (Camilleri & Tack, 2010; Enck, Klosterhalfen, & Martens, 2011); and 
food allergy (Gourbeyre et al., 2011; Schiavi, Barletta, Butteroni, Corinti, Boirivant, & Di Felice, 
2010a), but the possibilities for impacting many areas of health are numerous. Much research 
has been completed in efforts to understand and apply the natural benefits of non-pathogenic 
bacteria, but there is much still to do. 
New approaches to vaccination-based prophylaxis for Salmonella infection in poultry offer 
tremendous hope that highly effective vaccines may be on the horizion for commercial 
poultry. However, currently available and autogenous vaccines for Salmonella offer a modicum 
of protection that is generally only useful for breeders and laying hens at this time.  
Although there are occasional successes with treatment of enteric Salmonella infections in 
live birds with bacteriophage cocktails, as described above, resistance to bacteriophage lysis 
generally develops very quickly, leading most scientist to conclude that these offer little 
promise for treating Salmonella infections in live poultry. However, when broadly-effective 
bacteriophage cocktails have been applied to poultry carcasses at processing, these cocktails 
have been highly efficacious and potentially cost-effective for inducing marked reductions 
in Salmonella contamination (Higgins et al., 2005). This latter approach has the probability of 
avoiding the resistance issues associated with treatment of live animals in that Salmonella 
contaminants would only be exposed to the bacteriophage cocktail at a single point in the 
vertical production scheme, thereby avoiding re-introduction of resistant Salmonella isolates 
into the integrated poultry production operation.  
The scientific progress outlined in this chapter show highly encouraging progress toward 
intervention methods for Salmonella infections of poultry, and opportunities that are just 
becoming available to potentially impact poultry as a source of Salmonella-related food 
borne illness. Salmonella infections of poultry continue to be hugely problematic in both 
developed and developing countries. To date, no single “silver bullet” has been identified 
which can be applied commercially to eliminate this risk for this important and healthy 
human food source. Nevertheless, several tools, as described above, have been shown to be 
highly effective in reducing Salmonella levels in poultry production operations worldwide, 
particularly when used in combination. New probiotic/DFM products, with isolate selection 
based on better understanding of the mechanisms of efficacy, along with eventual 
regulatory approval and commercialization of exciting new vaccine technologies may make 
a tremendous impact in the very near future.  
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